Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Marta Olejniczak"'
Autor:
Anna Kotowska-Zimmer, Lukasz Przybyl, Marianna Pewinska, Joanna Suszynska-Zajczyk, Dorota Wronka, Maciej Figiel, Marta Olejniczak
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 28, Iss , Pp 702-715 (2022)
Among the many proposed therapeutic strategies for Huntington's disease (HD), allele-selective therapies are the most desirable but also the most challenging. RNA interference (RNAi) tools that target CAG repeats selectively reduce the mutant hunting
Externí odkaz:
https://doaj.org/article/f010f7696caf4052a9f3bf981d0f4f3f
Publikováno v:
Frontiers in Molecular Neuroscience, Vol 16 (2023)
Recent research integrates novel technologies and methods from the interface of RNA biology and neuroscience. This advancing integration of both fields creates new opportunities in neuroscience to deepen the understanding of gene expression programs
Externí odkaz:
https://doaj.org/article/fae6bb1058e64b6e8a3cf217cd1832c0
Autor:
Marianna Karwacka, Marta Olejniczak
Publikováno v:
Cells, Vol 11, Iss 3, p 517 (2022)
Polyglutamine (polyQ) diseases, including Huntington’s disease, are a group of late-onset progressive neurological disorders caused by CAG repeat expansions. Although recently, many studies have investigated the pathological features and developmen
Externí odkaz:
https://doaj.org/article/f48e660ebfad422cb2c1178668d22040
Publikováno v:
Stem Cell Research, Vol 39, Iss , Pp - (2019)
Dentatorubral–pallidoluysian atrophy (DRPLA) is an incurable autosomal dominant disease caused by an expansion of a CAG repeats in ATN1 gene encoding atrophin 1 protein. Here we report the generation of IBCHi001-A, an induced pluripotent stem cell
Externí odkaz:
https://doaj.org/article/6fcd3a28401b4ae0853172c525318109
Publikováno v:
Cells, Vol 9, Iss 5, p 1288 (2020)
The CRISPR-Cas system has become a cutting-edge technology that revolutionized genome engineering. The use of Cas9 nuclease is currently the method of choice in most tasks requiring a specific DNA modification. The rapid development in the field of C
Externí odkaz:
https://doaj.org/article/bb65dc18cb3648e1a5260dbeaf73deb8
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 5, p 1854 (2020)
Huntington’s disease (HD) is a fatal neurodegenerative disorder caused by the expansion of CAG repeats in exon 1 of the huntingtin gene (HTT). Despite its monogenic nature, HD pathogenesis is still not fully understood, and no effective therapy is
Externí odkaz:
https://doaj.org/article/41d300408fea40fcbc4ef3cec74049cb
Publikováno v:
Frontiers in Neuroscience, Vol 12 (2018)
Huntington's disease (HD) is a progressive autosomal dominant neurodegenerative disorder caused by the expansion of CAG repeats in the first exon of the huntingtin gene (HTT). The accumulation of polyglutamine-rich huntingtin proteins affects various
Externí odkaz:
https://doaj.org/article/bf49a027f96b4111a5cbb8b52f08e967
Publikováno v:
Mediators of Inflammation, Vol 2015 (2015)
Trinucleotide repeat expansion disorders (TREDs) are a group of dominantly inherited neurological diseases caused by the expansion of unstable repeats in specific regions of the associated genes. Expansion of CAG repeat tracts in translated regions o
Externí odkaz:
https://doaj.org/article/37572c72bccd4d8cb94bc016d42e2355
Autor:
Wlodzimierz J. Krzyzosiak, Agata Ciolak, Michał Michalak, Agnieszka Fiszer, Marta Olejniczak, Katarzyna Dorota Raczynska, Dominika Zielinska, Magdalena Wozna-Wysocka, Adam Ciesiolka, Emilia Kozlowska, Magdalena Dabrowska, Paweł Joachimiak, Anna Stroynowska-Czerwinska
Publikováno v:
Cellular and Molecular Life Sciences
Polyglutamine (polyQ) diseases are incurable neurological disorders caused by CAG repeat expansion in the open reading frames (ORFs) of specific genes. This type of mutation in the HTT gene is responsible for Huntington’s disease (HD). CAG repeat-t
Publikováno v:
Molecular Therapy. Nucleic Acids
The expansion of CAG repeats within the coding region of associated genes is responsible for nine inherited neurodegenerative disorders including Huntington’s disease (HD), spinocerebellar ataxias (SCAs), and dentatorubral-pallidoluysian atrophy (D